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The Cepheid Xpert MTB/RIF research-use-only (RUO) assay and a laboratory-developed test (LDT) tar-
geting IS6110 were evaluated and compared to mycobacterial culture as the gold standard. The performance
characteristics of both molecular assays were determined by using 112 specimens from 90 patients, including
89 pulmonary specimens and 23 extrapulmonary specimens. Of the specimens tested, 37 (33%) were culture
positive for the Mycobacterium tuberculosis complex; 29 were pulmonary, and 8 were extrapulmonary. Of these
culture-positive specimens, 83% of the pulmonary specimens and 50% of the extrapulmonary specimens were
smear positive. There was complete concordance between the smear-positive culture-positive specimens, in-
dependent of the anatomical site (100% sensitivity). The sensitivity of the MTB/RIF RUO assay for smear-
negative specimens was 60% for pulmonary and 75% for extrapulmonary specimens, while the IS6110 LDT
sensitivities were 40% and 0%, respectively. There was also complete concordance among the culture-negative
specimens tested. Both assays showed 95% specificity, with four culture-negative specimens testing as positive.
A review of patient records indicated that there was a high likelihood of the presence of M. tuberculosis complex
DNA in the false-positive specimens. Biosafety analysis was performed and showed an acceptable reduction in
organism viability using the processing methods described above. Both molecular assays are suitable for the
detection of M. tuberculosis isolates in smear-positive pulmonary and extrapulmonary specimens, while the
sensitivity of the detection of M. tuberculosis isolates in smear-negative specimens was variable.
Tuberculosis remains an important worldwide health con-
cern, with over 9 million new cases and approximately 2 million
deaths annually. Currently in the United States, there is only
one FDA-approved nucleic acid amplification test (NAAT) for
the Mycobacterium tuberculosis complex, the Gen-Probe Am-
plified Mycobacterium Tuberculosis Direct (MTD) test (San
Diego, CA). The Roche Amplicor Mycobacterium tuberculosis
complex (MTB) test was discontinued in 2010. A recently in-
troduced research-use-only (RUO) NAAT for the M. tubercu-
losis complex is the GeneXpert MTB/RIF assay (Cepheid,
Sunnydale, CA), which simultaneously detects the presence of
the M. tuberculosis complex and rifampin resistance directly
from respiratory specimens. The Xpert MTB/RIF assay is a
semiquantitative, nested, real-time PCR designed to amplify a
192-bp segment of the M. tuberculosis complex rpoB gene using
five overlapping molecular beacon probes that span the entire
81-bp rifampin-resistance-determining region. The MTB/RIF
assay also contains an internal control in which the detection of
lyophilized Bacillus atrophaeus subsp. globigii spores serves as
an internal processing and amplification control. Previous
work has demonstrated that the Xpert MTB/RIF assay displays
high percentages of sensitivity and specificity for the detection
of M. tuberculosis complex isolates, particularly in smear-pos-
itive respiratory specimens. Previously reported sensitivities
for smear-positive pulmonary specimens range from 95% to
100% (1, 4, 8, 11, 16), while sensitivities for smear-negative
pulmonary specimens vary between 55% and 75% (1, 4, 8, 11,
13, 16). Extrapulmonary specimens have shown 37% to 96%
sensitivity depending on the smear result and specimen type (1,
5, 9, 17). The specificities reported in all of the above-men-
tioned studies are excellent, ranging from 95% to 100%.
The interrogation of IS6110 has long been a valuable tool for
studying the epidemiology of the M. tuberculosis complex due
to its variability in copy number and genomic location (15). In
addition, it is a favored target for laboratory-developed tests
(LDTs) aimed at detecting M. tuberculosis in patient samples,
due largely to its multiple genomic copies and, therefore, in-
creased sensitivity. Mdivani et al. previously described an
IS6110 LDT applied to sputa obtained from patients receiving
anti-M. tuberculosis therapy (12). We adapted this LDT for use
in the current comparative evaluation. When analyzing a dif-
ferent IS6110 LDT, Armand et al. previously reported a 100%
sensitivity for smear-positive pulmonary and extrapulmonary
specimens and 68% and 71% sensitivities for smear-negative
pulmonary and extrapulmonary specimens, respectively (1).
By use of archived processed pulmonary and extrapulmo-
nary specimens, the Cepheid Xpert MTB/RIF RUO assay and
an IS6110 LDT were evaluated and compared to mycobacte-
rial culture as the gold standard. The performance character-
istics measured were analytical sensitivity and specificity, clin-
ical sensitivity and specificity, and biosafety.
* Corresponding author. Mailing address: UNC School of Medicine,
Department of Pathology and Laboratory Medicine, Campus Box
7525, Chapel Hill, NC 27599-7525. Phone: (919) 966-3723. Fax: (919)
966-0486. E-mail: mbmiller@unch.unc.edu.
† E.B.P. and M.G.B. contributed equally to the manuscript.
 Published ahead of print on 17 August 2011.
3458
MATERIALS AND METHODS
Study specimens. Specimens (n  112) used in this study were collected from
90 patients between August 2007 and April 2011 and stored at 70°C. Specimens
from 19 unique anatomical sites were tested (Table 1). Thirty-seven specimens
(33%) were positive for the M. tuberculosis complex by culture. Forty-seven
(42%) of the specimens had M. tuberculosis NAAT testing performed by a
reference laboratory per physician order (Gen-Probe MTD assay to May 2009
and Mayo Medical Laboratories LDT thereafter).
Mycobacterial culture and smear. All nonsterile specimens and normally
sterile specimens (biopsy specimens and aspirates) that were visibly bloody or
purulent were subjected to digestion and decontamination using the BBL
MycoPrep system (NALC [N-acetyl-L-cysteine]-NaOH) according to the manu-
facturer’s instructions (Becton Dickinson, Sparks, MD). After decontamination,
specimens were concentrated by centrifugation at 3,200  g for 15 min and
resuspended in 2 ml of sterile 0.067 M phosphate buffer (10). All specimens used
in this study were fully processed by digestion, decontamination, and concentra-
tion. Processed specimen sediment was used to inoculate a Becton Dickinson
Bactec MGIT tube and a Lowenstein-Jensen slant (Remel, Lenexa, KS), which
were incubated for 6 and 8 weeks, respectively. Smears of processed sediment
were stained with BBL TB Auramine-Rhodamine T (Becton Dickinson) and
reported as previously described (10).
Nucleic acid extraction. Total nucleic acids were extracted from processed
samples (phosphate buffer matrix) by using the Qiagen (Valencia, CA) BioRobot
EZ1 instrument. Briefly, specimens were treated with Qiagen buffer G2 at a ratio
of 4:1 (400 l G2 and 100 l specimen), boiled at 100°C for 30 min, and
centrifuged at 13,000  g for 3 min. A 200-l aliquot was removed from the
supernatant for extraction by using the Qiagen BioRobot EZ1 instrument. The
DNA tissue kit, DNA bacterial card, and bacterial protocol were utilized. Total
nucleic acids were eluted in 50 l of elution buffer, and 15 l of each extract was
used for nucleic acid amplification.
IS6110 real-time LDT. The IS6110 primers and probe sequences were previ-
ously described (12). For the LDT, 15 l of extracted nucleic acids was added to
35 l of a reaction mixture containing 900 nM each primer, 200 nM fluorophore
hydrolysis probe, and 25 l of TaqMan Universal PCR Master Mix (Life Tech-
nologies, Carlsbad, CA). Human albumin was amplified separately as an internal
control using the same concentrations and volumes described above (7). Cycling
conditions were 1 cycle at 50°C for 2 min and 1 cycle at 95°C for 10 min followed
by two-step PCR (40 cycles of 15 s at 95°C and then 1 min at 60°C). Amplification
and analysis were performed with the Applied Biosystems 7500 real-time PCR
system. Patient sample concentrations were determined by using a standard
curve derived from quantified DNA obtained from Advanced Biotechnologies
(Columbia, MD).
Xpert MTB/RIF RUO assay. The GeneXpert instrument (Cepheid, Sunnyvale,
CA) and Xpert MTB/RIF assay were described in detail previously (3, 4, 8).
According to the manufacturer’s RUO package insert, the sample reagent was
added to a decontaminated and concentrated specimen at a 3:1 ratio, the sample
container was agitated twice during a 15-min incubation at room temperature,
and 2 ml of the inactivated material was transferred into the Xpert cartridge.
Limit of detection and precision. The lower limit of detection (LLD) was
determined by two methods. First, serial dilutions of M. tuberculosis H37Rv
quantitated bacterial DNA (Advanced Biotechnologies) with a DNA copy num-
ber of 1.3  104 DNA copies/l (determined by the manufacturer’s in-house
real-time PCR) was used unextracted. Second, M. tuberculosis (ATCC 27294)
was grown in 7H11 broth (Remel, Lenexa, KS) for 7 days and then diluted in
sterile saline, plated onto 7H11 agar (Remel), and extracted. Dilutions were
stored at 4°C. CFU per ml were calculated based on the serial plating of dilutions
prior to nucleic acid extraction. Precision calculations were performed according
to CLSI guidelines (6), using either triplicate testing over three consecutive days
or five replicates over five consecutive days, as indicated. All replicates had to be
positive to define the LLD.
Analytical specificity. Bacterial strains were obtained from clinical cultures
and ATCC stocks. Sterile saline solutions of bacterial strains were prepared at a
2.0 McFarland standard, and pools of three to five organisms were tested. For
adenovirus, cytomegalovirus, enterovirus, herpes simplex viruses 1 and 2, meta-
pneumovirus, rhinovirus, and varicella-zoster virus, stocks were obtained by
harvesting cell cultures at a 50% cytopathic effect. For Epstein-Barr virus
(Acrometrix, Benicia, CA), human herpesvirus 6 (Advanced Biotechnologies),
and parvovirus (ZeptoMetrix, Buffalo, NY), the estimated quantities tested were
2.5  104 copies, 1.2  109 viral particles, and 1.0  106 IU, respectively. The
remaining respiratory viruses tested were ZeptoMetrix qualitative controls. Vi-
ruses were tested in pools of 5 to 8.
Biosafety assessment. Two experiments were conducted to assess postprocess-
ing viability. To test the extraction method used for the IS6110 LDT, 10 smear-
positive (3) M. tuberculosis complex culture-positive samples were plated onto
7H11 agar after the centrifugation step. In addition, the M. tuberculosis complex
control strain (ATCC 27294) was also processed through centrifugation and
plated separately onto five plates over 5 days. To assess the extraction method
used for the GeneXpert assay, 3.4  109 CFU/ml of the M. tuberculosis complex
control strain in sterile saline solution, 1.1  106 CFU/ml of a patient-sourced M.
tuberculosis complex isolate in sterile saline solution, and a sedimented patient
sample previously smear positive (2 quantification) and culture positive for M.
tuberculosis were obtained. The patient sample concentration based on quanti-
fication by real-time IS6110 PCR was 3.7  104 CFU/ml. On three consecutive
days, each sample was processed according to the Xpert MTB/RIF RUO pack-
age insert, and 100 l of each lysate was then plated onto 7H11 medium in
triplicate.
Statistical analysis. P values were determined for independent samples by
using a two-tailed Student t test. Confidence intervals (CIs) were determined by
using GraphPad software (GraphPad, La Jolla, CA).
This study was approved by the Institutional Review Board of the University
of North Carolina at Chapel Hill.
RESULTS
Analytical sensitivity and specificity. For the IS6110 LDT,
the LLD using the commercial quantified DNA was deter-
mined to be 0.2 copies per reaction or 3.3 copies per ml, with
a mean cycle threshold (CT) of 35.6 (95% CI, 34.9 to 36.3). The
LLD for the ATCC strain of M. tuberculosis was determined to
be 1,241 CFU/ml, with a mean CT value of 35.4 (95% CI, 35.1
to 35.7). Precision testing of the 1,241 CFU/ml over 5 days
demonstrated an intrarun precision of 0.56 CT (coefficient of
variation [CV], 1.6%), and the total precision was 0.75 CT (CV,
2.1%). Lower limit analysis of the Xpert MTB/RIF assay was
performed using only the M. tuberculosis ATCC strain, as the
quantified DNA could not be analyzed by the GeneXpert sys-
tem. The Xpert LLD was determined to be 786 CFU/ml, with
TABLE 1. Clinical specimens used for comparative evaluation by M. tuberculosis complex culture result
Specimen
Sample types (no. of specimens)
M. tuberculosis complex negative (n  75) M. tuberculosis complex positive (n  37)
Pulmonary Bronchial brush (1), bronchial wash (5), bronchoalveolar lavage
(11), expectorated sputum (24), induced sputum (17), lung
biopsy specimen (4), nasopharyngeal aspirate (1), pleural
fluid (2), sputum (unspecified) (3), tracheal aspirate (2)
Bronchial wash specimen (1), bronchoalveolar lavage
fluid (3), expectorated sputum (9), induced
sputum (15), pleural biopsy specimen (1), pleural
fluid (1), sputum (unspecified) (1)
Extrapulmonary Brain biopsy specimen (2), lymph node biopsy specimen (2),
sinus biopsy specimen (1)
Endometrial biopsy specimen (1), lymph node biopsy
specimen (1), neck abscess aspirate (1), neck mass
biopsy specimen (1), retroperitoneal fluid (1),
stool (1)
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a mean CT of 36.4 (95% CI, 35.9 to 36.9). The within-run
precision of the 786 CFU/ml performed over 3 days was 0.86
CT (CV, 2.1%), and the total precision equaled 0.94 CT (CV,
2.4%). Previous studies have found the LLD of the Xpert assay
to be 131 CFU/ml using spiking experiments with residual
sputa (8).
Table 2 lists the bacteria and viruses that were tested to
assess the analytical specificities of both molecular assays. No
cross-reactivity was observed. In addition, the specimens used
in this study were also culture positive for a variety of organ-
isms, which are listed in Table 2. None of these clinical spec-
imens was positive for the M. tuberculosis complex by either
molecular assay.
Clinical sensitivity. Of the 112 specimens used in this study,
37 (33%) were culture positive for the M. tuberculosis complex;
9 (24%) were smear negative, and 28 (76%) were smear pos-
itive at the following quantities: 1 smear (n  5), 2 smear
(n  8), and 3 smear (n  15). Both the IS6110 LDT and the
Xpert MTB/RIF assay detected all smear-positive specimens,
which included 24 respiratory specimens (Table 1) and 4 non-
respiratory specimens, including a neck abscess aspirate, stool
specimen, lymph node biopsy specimen, and retroperitoneal
aspirate. The reference laboratory NAAT was performed on
20 of the smear-positive specimens, including 3 of the non-
respiratory specimens (neck abscess aspirate, stool specimen,
and lymph node aspirate), and all were positive.
There was, however, a difference in the performances of
Xpert MTB/RIF assay and the IS6110 LDT for the smear-
negative culture-positive specimens (n  9) (Table 3). The
IS6110 LDT detected only two of nine specimens (22%), while
the Xpert MTB/RIF assay detected six (67%). The three spec-
imens missed by both assays were expectorated sputum, in-
duced sputum, and a pleural biopsy specimen. In addition, the
IS6110 LDT missed a bronchial wash specimen, a neck mass
biopsy specimen, an endometrial biopsy specimen, and pleural
fluid. None of the smear-negative culture-positive specimens
were tested by the reference laboratory molecular test. The
time to culture positivity was calculated for each of the follow-
ing groups: positive by both tests, positive by the Xpert assay
only, and negative by both tests. There was not a statistical
difference in the time to culture positivity for any comparison.
The time of freezer storage was also compared for each group.
TABLE 2. Organisms tested for analytical specificitya




























Herpes simplex viruses 1 and 2 (1)
Human herpesvirus 6 (1)
Influenza A virus (1)
Influenza B virus (1)
Metapneumovirus (1)
Parainfluenza viruses 1, 2, and 3 (1)
Parvovirus (1)









Mycobacterium abscessus group (2)
Mycobacterium avium complex (14)









a Bacteria and viruses were tested directly at high titers. Clinical specimens are
organisms that were cultured from the M. tuberculosis complex-negative speci-
mens.
TABLE 3. Clinical sensitivity and specificity of the Xpert MTB/RIF
RUO assay and the IS6110 LDT using culture as the gold standard
Test
% value (no. of specimens positive
by NAAT/no. of specimens
positive by culture)
Xpert MTB/RIF
RUO assay IS6110 LDT
All sites (n  112)
Sensitivity, all 92 (34/37) 81 (30/37)
Sensitivity, smear positive 100 (28/28) 100 (28/28)
Sensitivity, smear negative 67 (6/9) 22 (2/9)
Specificity 95 (71/75) 95 (71/75)
Pulmonary sites (n  89)
Sensitivity, all 93 (27/29) 90 (26/29)
Sensitivity, smear positive 100 (24/24) 100 (24/24)
Sensitivity, smear negative 60 (3/5) 40 (2/5)
Specificity 97 (58/60) 97 (58/60)
Extrapulmonary sites (n  23)
Sensitivity, all 88 (7/8) 50 (4/8)
Sensitivity, smear positive 100 (4/4) 100 (4/4)
Sensitivity, smear negative 75 (3/4) 0 (0/4)
Specificity 87 (13/15) 87 (13/15)
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Culture-positive specimens that were negative by both assays
(n  3) were on average 915 days old (95% CI, 762 to 1,068),
whereas those detected by at least one of the assays (n  6)
were on average 443 days old (95% CI, 116 to 770). This
difference was statistically significant (P  0.03). Thus, the
length of the specimen storage time may have contributed to
the decrease in sensitivity seen with smear-negative specimens,
but it is also well established that smear-negative specimens
have a lower sensitivity due to the lower organism load present
in the sample.
Clinical specificity. Seventy-one of 75 specimens (95%) pre-
viously determined to be culture negative for the M. tubercu-
losis complex were negative by both the IS6110 LDT and the
Xpert MTB/RIF assays. Of the M. tuberculosis culture-negative
specimens, 30 (40%) were smear positive and either grew an-
other organism (n  22) (see “Analytical sensitivity and spec-
ificity” above) or showed no growth (n  8). The four false-
positive specimens included brain (negative smear), induced
sputa (n  2) (1 and 3 smears), and lymph node aspirate
(1 smear).
Discrepant analysis. The four seemingly false-positive spec-
imens were obtained from three patients. A clinical chart re-
view of these three patients indicated the following. Patient 1
had a brain biopsy specimen that was smear negative and
culture negative but positive by both the IS6110 LDT and
Xpert MTB/RIF assay. The reference laboratory NAAT was
also positive. The patient had a history of noncavitary pulmo-
nary tuberculosis 6 months prior to presenting with seizures
and an enlarging brain lesion. The patient was receiving rifam-
pin and isoniazid at the time of presentation, although drug
levels were determined to be low. The clinical diagnosis was a
brain tuberculoma, which was treated and improved. Patient 2
had two induced sputa that were smear positive but culture
negative. Both specimens were also positive by the reference
laboratory NAAT. This patient had a history of pulmonary
tuberculosis for which therapy was completed 14 months ear-
lier. The patient presented with a 1-week history of fever, night
sweats, and dark urine. Both the patient’s sister and daughter
were currently being treated for tuberculosis. The final diag-
nosis of the patient was community-acquired pneumonia.
However, the patient received four-drug M. tuberculosis ther-
apy through the health department until sputa were smear
negative. Patient 3 was recently diagnosed with uterine carci-
noma. She presented with hilar lymphadenopathy not respond-
ing to her current chemotherapy. The lymph node aspirate was
smear positive, culture negative, and NAAT positive by both
the IS6110 LDT and Xpert MTB/RIF assay but negative by a
reference laboratory NAAT. Of note, the referred NAAT was
performed on the native specimen, while the evaluation
NAATs were performed on a decontaminated and concen-
trated specimen. The pathology of the lymph node showed
both necrotizing and nonnecrotizing granulomatous inflamma-
tion. The patient’s father was diagnosed with active tubercu-
losis 3 months prior, and the patient had recently converted
her purified protein derivative (PPD) reaction. The patient had
no lung abnormalities, and thus, three induced sputa were
negative for the M. tuberculosis complex by smear and culture.
The patient received four-drug therapy for tuberculosis. Based
on the above-described clinical findings, these culture-nega-
tive, NAAT-positive specimens are likely truly positive for M.
tuberculosis complex DNA, although the organisms may not
have been viable.
Biosafety. To test the biosafety of the processing protocol for
the IS6110 LDT, processed smear-positive patient specimens
(n  10) and the M. tuberculosis control strain were cultured
prior to the placement of the lysates onto the extraction equip-
ment to assess organism viability. No growth was observed for
any of the replicates after 3 months of incubation. To ascertain
safety for the extraction method used for the Xpert MTB/RIF
assay, we assessed the viability of high titers of an M. tubercu-
losis control strain, a patient M. tuberculosis isolate, and a
sedimented positive patient sample. Cultures of the lysate
prior to pipetting into the GeneXpert cartridge showed no
growth except for two of three replicates for one sedimented
patient specimen. Cultures indicated that 30 CFU/ml survived
the lysis process. These data indicate a complete inactivation of
the high-concentration M. tuberculosis complex solutions and a
1,000-fold reduction in the viability of M. tuberculosis in the
patient sample. This is in line with previously reported stan-
dards (14). Likewise, Banada et al. previously demonstrated a
6-log-unit reduction in viability when Xpert lysates were
tested (2).
DISCUSSION
A summary of the sensitivity and specificity data for the
IS6110 LDT and the Xpert MTB/RIF assay can be found in
Table 3. Both assays detected smear-positive respiratory and
smear-positive nonrespiratory specimens (neck abscess aspi-
rate, stool sample, lymph node biopsy specimen, and retroper-
itoneal aspirate) accurately. The overall sensitivity was higher
for the Xpert MTB/RIF assay due to a better detection of
smear-negative specimens, although this was not statistically
significant (P  0.18). The LLD was observed to be lower for
the Xpert MTB/RIF assay than for the IS6110 LDT (786
CFU/ml and 1,241 CFU/ml, respectively), which likely contrib-
utes to the improved sensitivity of the Xpert assay. However,
the LLDs were determined by using a sterile saline matrix as
opposed to negative processed sediments. While our reported
LLD values may not truly reflect the actual values for clinical
specimens (and this may vary by specimen type), the LLD
analysis of the two molecular tests provides a means for com-
paring the relative analytical sensitivities of the assays. Using
quantification by real-time IS6110 PCR, the range of M. tuber-
culosis loads in patient samples was 187 to 2.0  1012 CFU/ml,
with a median of 1.6  106 CFU/ml and mean of 1.0  1011
CFU/ml. Specimens that were Xpert MTB/RIF positive and
IS6110 LDT negative had estimated quantities of M. tubercu-
losis of 996 to 4,000 CFU/ml. The specificities of both tests
relative to culture were 95%, but a discrepant analysis was
performed by chart review. Clinical history and patient man-
agement indicated that although these patients had culture-
negative specimens, they likely had M. tuberculosis complex
DNA present in the sample. It is well accepted that molecular-
based approaches to the diagnosis of infectious disease will
lead to positive DNA results in the absence of viable organ-
isms. Three of the four patient samples were also smear pos-
itive. Negative and positive predictive values could not be cal-
culated because this was a study of convenience samples, not
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preserving the incidence of M. tuberculosis complex detection
at our institution (1%).
The rifampin screening component of the MTB/RIF assay
was not fully evaluated during the study period due to the low
incidence of rifampin-resistant M. tuberculosis in our patient
population. Of the specimens tested, only four were positive
for rifampin resistance by the Xpert assay. Three were rifam-
pin resistant by phenotypic methods, while one was phenotyp-
ically rifampin susceptible. The Centers for Disease Control
and Prevention Tuberculosis Molecular Detection of Drug Re-
sistance service identified a silent mutation (Phe514Phe) in the
rifampin-susceptible M. tuberculosis complex isolate. Based on
the specimens tested in this study, the sensitivity of the rifam-
pin resistance component of the assay was 100%. Further test-
ing is warranted to fully assess the positive predictive value of
rifampin resistance detection in areas of low prevalence.
Limitations of this study include the retrospective design,
which was necessary due to the low prevalence of M. tubercu-
losis in our community. While cultures were performed in real
time, the molecular analysis was done much later. As a result
of the low prevalence, specimens were stored for an extensive
time prior to testing. It appears that the length of storage had
an impact on the sensitivity of the IS6110 LDT. A prospective
analysis of smear-negative specimens would provide a clearer
view of the true sensitivity. Also, only processed (digested/
decontaminated and concentrated) specimens were used in
this evaluation. The waiting time for specimen processing in-
creases the time to a result for both molecular tests. Ideally,
direct unprocessed specimens should be tested for the greatest
impact of results. Notably, the Xpert RUO package insert
provides instructions for direct specimen processing. For as-
sessing the performance characteristics of extrapulmonary
specimens, we had a paucity of culture-positive specimens (n 
8), and only 50% of them were smear positive. Thus, the
calculated performance characteristics with extrapulmonary
specimens may not be representative of a larger sample size.
Lastly, we used culture as the gold standard. While this is the
most convenient reference method, it may not be the best
standard, as indicated by a discrepant analysis performed by
chart review. Since our reference laboratory used both the
GenProbe MTD assay and an LDT during the course of this
study, we could not include the analysis of an FDA-approved
NAAT performed on study specimens. Furthermore, a refer-
ence NAAT was performed only upon physician request, lead-
ing to an incomplete data set for comparison.
The Xpert MTB/RIF RUO assay and the IS6110 LDT per-
formed identically for all smear-positive specimens (pulmo-
nary and extrapulmonary). The MTB/RIF assay detected more
of the smear-negative culture-positive specimens than did the
IS6110 LDT, likely due to differences in the analytical sensi-
tivities of the assays. Although the sensitivity for smear-nega-
tive specimens with either assay is suboptimal, the Xpert MTB/
RIF sensitivity is decent, at 67%, compared to 22% for the
LDT (Table 3). In the context of high test specificity, a rapid
positive result for a smear-negative respiratory specimen
would positively impact patent care and public health efforts.
However, multiple sequential tests may be needed to increase
the sensitivity to provide actionable negative results for smear-
negative specimens (4).
The Xpert assay has a 15-min hands-on time and a 113-min
run time, while the IS6110 LDT has a 30-min hands-on time
and a 147-min run time (extraction and amplification). Unlike
the IS6110 LDT, which requires batch processing and molec-
ular proficiency, the MTB/RIF assay is a random-access assay
and does not require molecular expertise to perform. There is
a great need for rapid, accurate in vitro diagnostic products for
the early diagnosis of tuberculosis, even in low-prevalence ar-
eas such as the United States. Our evaluation of the Xpert
MTB/RIF RUO assay demonstrates that such a test is realistic.
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